InflaRx N.V.
NASDAQ:IFRXBiotechnology
Healthcare
$1.09 -0.82%
-$0.02 today
- Market cap
- $160.63M
- Beta
- 2.44
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.59
52W Low $0.74High $2.95
Volume 0.66M
Average 1.80M
Income Statement
Follow revenue through to earnings.
Revenue
$29,331.00
FY 2025 · Annual
-82.3% YoYOperating Income
-$48.26M
FY 2025 · Annual
Net Income
-$45.63M
FY 2025 · Annual
Income Statement
EUR
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 63.09K | 165.79K | 29.33K |
| Cost of Revenue | 0 | 0 | 532.26K | 3.32M | 7.27M |
| Gross Profit | 0 | 0 | (469.17K) | (3.15M) | (7.24M) |
| Gross Margin | — | — | -743.7% | -1900.8% | -24677.9% |
| Research & Development | 35.7M | 37.53M | 41.02M | 35.36M | 25.72M |
| Selling, General & Admin | 11.43M | 14.34M | 16.12M | 19.33M | 17.56M |
| Operating Expenses | 47.63M | 32.24M | 44.13M | 49.75M | 41.02M |
| Depreciation & Amortization | 669.43K | 596.6K | 567.78K | 485.11K | 419.48K |
| EBITDA | (44.94M) | (28.84M) | (42.06M) | (45.55M) | (45.16M) |
| EBITDA Margin | — | — | -66674.3% | -27476.7% | -153976.3% |
| Operating Income | (47.63M) | (32.24M) | (44.59M) | (52.91M) | (48.26M) |
| Operating Margin | — | — | -70685.6% | -31911.4% | -164525.5% |
| Interest Income | 109.39K | 608.68K | 3.8M | 3.2M | 1.77M |
| Interest Expense | 24.77K | 45.25K | 35.63K | 20.66K | 37.69K |
| Other Income / Expenses | 2M | 2.75M | 1.93M | 6.85M | 2.64M |
| Income Before Tax | (45.63M) | (29.48M) | (42.67M) | (46.06M) | (45.62M) |
| Pre-Tax Margin | — | — | -67630.7% | -27781.8% | -155540.2% |
| Income Tax Expense | 0 | 0 | 0 | 5.22K | 12.28K |
| Net Income | (45.63M) | (29.48M) | (42.67M) | (46.06M) | (45.63M) |
| Net Margin | — | — | -67630.7% | -27785.0% | -155582.1% |
| EPS (Basic) | (1.10) | (0.61) | (0.78) | (0.78) | (0.66) |
| EPS (Diluted) | (1.10) | (0.61) | (0.78) | (0.78) | (0.66) |
| 41.63M | 44.21M | 54.94M | 58.92M | 67.29M | |
| 41.63M | 44.21M | 54.94M | 58.92M | 67.29M |
IFRX Earnings Waterfall · TTM
NASDAQ:IFRX · Revenue to Net Income
Key Ratios
EPS$-0.61
Gross Margin2132.9%
Net Margin-14161.8%
P/E Ratio-1.6
P/S Ratio673.2
Analysis
$29.3K of revenue converted into -$42.9M of net income for the selected period. Gross margin is 2132.9% and net margin is -14161.8%, showing how much revenue survives after costs and taxes. EPS is $-0.61, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 6, 2026 | |
| 6-K | 6-K filing | Nov 3, 2026 | |
| 6-K | 6-K filing | Nov 3, 2026 | |
| 6-K | 6-K filing | Oct 22, 2026 | |
| SC 13G | SC 13G filing | Aug 17, 2026 |
How much revenue does IFRX generate?
InflaRx N.V. (IFRX) reported $29,331.00 of revenue in fiscal 2025.
Is IFRX profitable?
InflaRx N.V. (IFRX) reported -$45.63M of net income, with a net margin of -155582.1%.
Continue the stock analysis
Jump to another research area for this company.